KlearNews
LIVE
Just published.
Human review coming soon.

Novo Nordisk Weight Loss Drug Fails Trial

Novo Nordisk announced a drug trial failure on Monday. The company's weight loss drug did not meet its main goal.

The drug achieved only 23% weight loss. This was lower than existing treatments.

Patients receive the drug as a once-a-week injection. Novo Nordisk's stock fell 15% on Monday.

The company is based in Copenhagen, Denmark. Denmark's stock market fell alongside Novo Nordisk's decline.

Klear Note Novo Nordisk makes popular weight loss drugs used by millions worldwide. When big companies' stock prices fall sharply, it affects entire stock markets.

Key Terms 1
Novo Nordisk
Danish company that makes obesity and weight loss drugs
Verified Sources 4